Risk factors
Onconetix (ONCO) risk factors
Item 1A of every Onconetix, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors91 risks9 new8 dropped11 reworded
Onconetix pivoted its strategy by abandoning ENTADFI commercialization, settling its Veru debt, and pursuing the Realbotix transactions.
Filed Mar 13, 2026 - FY2024 10-K risk factors90 risks
Company faces severe going concern doubt with only $0.6 million in cash against $18.3 million in current liabilities. Operations rely heavily on single products like Proclarix and ENTADFI, and key partners like LabCorp and Veru.
Filed Jun 02, 2025